Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 3, 369-76

Review of Interferon beta-1b in the Treatment of Early and Relapsing Multiple Sclerosis

Affiliations

Review of Interferon beta-1b in the Treatment of Early and Relapsing Multiple Sclerosis

Damiano Paolicelli et al. Biologics.

Abstract

Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFNbeta)-1b represents the pioneer of those therapies. There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFNbeta-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging. Long-term data suggest a persistent efficacy of IFNbeta-1b on disease activity and a positive effect in slowing disability worsening. Furthermore a reduction of relapse rate and a slight positive effect on the progression were demonstrated when IFNbeta-1b was administered to still-active secondary progressive MS. IFNbeta-1b therapy is well tolerated and relatively free of long-term side effects. In spite of the emergence of new agents for the treatment of MS, IFNbeta-1b still remains a first-line therapy with a fundamental role in all stages of the disease.

Keywords: clinically isolated syndromes; efficacy; interferon beta-1b; neutralizing antibodies; relapsing-remitting multiple sclerosis; safety.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

References

    1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multi-center, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–661. - PubMed
    1. Paty DW, Li DK. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. II.MRI analysis results of a multicenter, randomized, double blind, placebo controlled trial. UBC MS/MRI Study Group and The IFN beta multiple sclerosis study group. Neurology. 1993;43:662–667. - PubMed
    1. European Study Group on Interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive MS. Lancet. 1998;352:1491–1497. - PubMed
    1. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242–1249. - PubMed
    1. Kappos L, Freedman MS, Polman CH, et al. BENEFIT Study Group. Effect of early vs delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:89–97. - PubMed

LinkOut - more resources

Feedback